Potentiation of murine MCA-4 carcinoma radioresponse by 9-amino-20(S)- camptothecin

Cancer Research

Volumn 57, Issue 10, 1997, Pages 1929-1933

  Kirichenko, Alexander V ^a   Rich, Tyvin A ^a   Newman, Robert A ^a   Travis, Elizabeth L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; CESIUM 137; RADIOSENSITIZING AGENT;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; INTESTINE INJURY; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; SKIN INJURY; TREATMENT OUTCOME; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; RADIATION-SENSITIZING AGENTS;

EID: 0030965077     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 54: 665-697, 1985.
2. Osheroff, N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol. & Ther., 41: 223-241, 1989.
3. Hsiang, Y-H., Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Kirschenbaum, S., Silber, R., and Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res., 49: 4385-4389, 1989.
4. Pommier, Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother. Pharmacol., 32: 103-108, 1993.
5. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
6. Boothman, D. A., Fukunada, N., and Wang, M. Down-regulation of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res., 54: 4618-4626, 1994.
7. Boothman, D. A., Waugh, M., Schea, R. A., Burrows, H. L., Strickfaden, S., and Owens, J. K. Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys., 24: 939-948, 1992.
8. Mattern, M. R., Hoffman, G. A., McCabe, F. L., and Johnson, R. K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK and F104864). Cancer Res., 51: 5813-5816, 1991.
9. Falk, S. J., and Smith, P. J. DNA damaging and cycle effects of the topoisomerase I poison camptothecins in irradiated human cells. Int. J. Radiat. Biol., 61: 749-757, 1992.
10. Del Bino, G., Bruno, S., Yi, P. N., and Darzynkiewicz, Z. Apoptotic cell death triggered by camptothecin or teniposide: the cell cycle specificity and effects of ionizing radiation. Cell Proliferation, 25: 537-548, 1992.
11. Hennequin, C., Giocanti, N., Balosso, J., and Favaudon, V. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res., 54: 1720-1728, 1994.
12. Lamond, J. P., Wang, M., Kinsella, T. J., and Boothman, D. A. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. Int. J. Radiat. Biol., 36: 361-368, 1996.
13. Lamond, J. P., Wang, M., Kinsella, T. J., and Boothman, D. A. Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors. Int. J. Radiat. Biol., 36: 369-376, 1996.
14. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res., 56: 4430-4437, 1996.
15. Morris, E. J., and Geller, H. M. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase I: evidence for cell cycle-independent toxicity. J. Cell Biol., 134: 757-770, 1996.
16. Kim, J. H., Kim, S. H., Kolozsvary, A., and Khil, M. Potentiation of radiation response in human carcinoma cells in vitro with murine fibrosarcoma in vivo by topotecan. Int. J. Radiat. Oncol. Biol. Phys., 22: 515-518, 1992.
17. Boscia, R. E., Korbut, T., Holden, S. A., Ara, G., and Teicher, B. A. Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FASTS fibrosarcoma in vivo. Int. J. Cancer, 53: 118-123, 1993.
18. Roffler, S. K., Chan, V., and Yeh, M. Y. Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res., 54: 1276-1285, 1994.
19. Giovanella, B. C., Hinz, H. R., Kozielski, A. J., Stehlin, J. S., Jr., Silber, R., and Potmesil, M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res., 51: 3052-3055, 1991.
20. Milas, L., Hunter, N., Mason, K., and Withers, H. R. Immunological resistance to pulmonary metastases in C3Hf/Bu mice bearing syngeneic fibrosarcoma of different sizes. Cancer Res., 34: 61-71, 1974.
21. Roberts, D. B., and Travis, E. L. Acemannan-containing wound dressing gel reduces radiation-induced skin reactions in C3H mice. Int. J. Radiat. Oncol. Biol. Phys., 32: 1047-1052, 1995.
22. Travis, E. L., Fang, M. Z., and Basic, I. Protection of mouse bone marrow by WR-2721 after fractionated irradiation. Int. J. Radiat. Oncol. Biol. Phys., 15: 377-382, 1988.
23. Takimoto, C. H., Klecker, R. W., Dahut, W. L., Yee, L. K., Strong, J. M., Allegra, C. J., and Grem, J. L. Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J. Chromatogr., 655: 97-104, 1994.
24. Withers, H. R., and Elkind, M. M. Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. Int. J. Radiat. Biol., 17: 261-267, 1970.
25. Masuda, K., Matsuura, K., Withers, H. R., and Hunter, N. Response of previously irradiated mouse skin to a second course of irradiation: early skin reaction and skin shrinkage. Int. J. Radiat. Oncol. Biol. Phys., 12: 1645-1651, 1986.
26. Potmesil, M. Camptothecins: from bench research to hospital wards. Cancer Res., 54: 1411-1439, 1994.
27. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattern, M. R., Mong, S-M., Bartus, J. O., Johnson, R. K., and Kingsbury, W. D. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32: 715-720, 1989.
28. Houghton, D. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
29. Covey, J. M., Jaxel, C., Kohn, K. W., and Pommier, Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res., 49: 5016-5022, 1989.
30. Ohno, K., Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, M., Ishimaru, M., Sakai, Y., Oguro, M., Ito, Y., Morishima, Y., Kokomaku, S., and Ota, K. An early Phase II study of CPT-II: a new derivative of camptothecin for the treatment of leukemia and lymphoma. J. Clin. Oncol., 8: 1907-1912, 1990.
31. Araki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M., and Hoshi, A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-II, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT II. Jpn. J. Cancer Res., 87: 697-702, 1993.